If the data are positive, the companies said they can request regulatory approval in the first half of 2021. Sanofi will get the bulk of the funds. The vaccine candidate is the sixth now in development under the program, which has also made deals with AstraZeneca, Johnson & Johnson, Moderna, Novavax and Pfizer.
The latest collaboration is the largest grant yet under the Trump administration's "Operation Warp Speed", an initiative focused on developing an accessible COVID-19 vaccine by the end of the year.
While clinical trials are underway, HHS said, manufacturing efforts would begin with a demonstration project-a parallel effort meant to speed up vaccine development.More news: Epstein's ex-girlfriend tries late bid to seal testimony
The contract is the latest in a series of deals - potentially worth more than $8 billion - struck by the US government aimed at accelerating development of Covid-19 vaccines and securing large supplies before potential product approvals. We are expecting more vaccines from the companies soon.
"We are searching for more volunteers and if any one who is healthy, class 12 passed and between 18 and 55 years of age wants to becomea volunteer for clinical trial and join hands against Covid-19 could contact us at phone numbers, 8303028051 and 6388214084", he added. However, health care providers could charge to administer the vaccine.
"Pharmaceutical companies have been under pressure to keep COVID-19 therapies and vaccines affordable, particularly when the federal government - and taxpayers - have offered substantial funding toward research and development", NRP's Sydney Lupkin said.
- The US government is to pay Sanofi and GlaxoSmithKline $2.1 billion to cover vaccines for 50 million people.More news: Boston Marathon bombing: Dzhokhar Tsarnaev's death sentence overturned
The companies said the USA government will provide up to $2.1 billion for development, manufacturing and delivery.
"The (vaccine) doses would be manufactured in European countries including France, Belgium, Germany, and Italy", the companies said in a statement.
In addition, GSK and Sanofi plan to provide a "significant" portion of their total worldwide available supply capacity in 2021 and 2022 to "Access to COVID‐19 Tools (ACT) Accelerator", a global collaboration created to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
The World Health Organization is among global organizations participating in the ACT accelerator effort, along with the Bill & Melinda Gates Foundation; the Coalition for Epidemic Preparedness Innovations (CEPI); the Foundation for Innovative New Diagnostics (FIND); Gavi, The Vaccine Alliance; The Global Fund; Unitaid;, Wellcome; The World Bank; and the World-Bank-supported Global Financing Facility.More news: Alan Parker, director of Midnight Express dies at 76